Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - HC Wainwright decreased their FY2028 earnings per share estimates for Delcath Systems in a report released on Monday, November 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of $1.46 for the year, down from their prior estimate of $1.69. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($1.64) per share.
A number of other equities research analysts have also weighed in on DCTH. Canaccord Genuity Group restated a "buy" rating and set a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised Delcath Systems from a "sell" rating to a "hold" rating in a report on Friday, October 25th. Finally, Stephens reaffirmed a "buy" rating on shares of Delcath Systems in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.50.
Read Our Latest Stock Analysis on Delcath Systems
Delcath Systems Price Performance
Shares of DCTH stock traded up $0.05 during trading hours on Wednesday, reaching $9.75. The company had a trading volume of 200,321 shares, compared to its average volume of 272,026. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $12.88. The stock's fifty day simple moving average is $9.74 and its 200 day simple moving average is $8.43.
Hedge Funds Weigh In On Delcath Systems
Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. acquired a new stake in Delcath Systems during the third quarter valued at $808,000. Riverwater Partners LLC acquired a new stake in Delcath Systems in the 3rd quarter valued at about $161,000. Cubist Systematic Strategies LLC acquired a new stake in Delcath Systems in the 2nd quarter valued at about $370,000. Shellback Capital LP bought a new position in shares of Delcath Systems during the second quarter worth approximately $1,353,000. Finally, Marshall Wace LLP increased its holdings in shares of Delcath Systems by 7.0% during the second quarter. Marshall Wace LLP now owns 92,731 shares of the company's stock worth $776,000 after purchasing an additional 6,066 shares during the period. 61.12% of the stock is currently owned by institutional investors and hedge funds.
Delcath Systems Company Profile
(
Get Free Report)
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Featured Articles
Before you consider Delcath Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delcath Systems wasn't on the list.
While Delcath Systems currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
